Last reviewed 2026-04-20 · How we verify

Phentonium (FENTONIUM)

Phase 2 active Small molecule

Phentonium (generic name: FENTONIUM) is a fentonium drug. It is currently in Phase 2 development.

Fentonium is thought to work by interacting with a specific molecular target, although the exact nature of this interaction is not well understood.

Fentonium, also known as Phentonium, is a small molecule drug of the fentonium class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. The commercial status of Fentonium is unclear, with no information available on its patent status, generic manufacturers, or off-patent status. Further research is needed to understand the properties and potential uses of Fentonium. As a result, there is limited information available on its safety profile and pharmacokinetic properties.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FENTONIUM
Drug class	fentonium
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Fentonium is a key that fits into one of those locks. When it binds to the lock, it can either open the lock to allow something in or out, or it can block the lock to prevent something from getting in or out. This can affect how the cell works and responds to signals.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Phentonium CI brief — competitive landscape report
Phentonium updates RSS · CI watch RSS

Frequently asked questions about Phentonium

What is Phentonium?

Phentonium (FENTONIUM) is a fentonium drug.

How does Phentonium work?

Fentonium is thought to work by interacting with a specific molecular target, although the exact nature of this interaction is not well understood.

What is the generic name of Phentonium?

FENTONIUM is the generic (nonproprietary) name of Phentonium.

What drug class is Phentonium in?

Phentonium belongs to the fentonium class. See all fentonium drugs at /class/fentonium.

What development phase is Phentonium in?

Phentonium is in Phase 2.

Drug class: All fentonium drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing